Prudential PLC United Therapeutics Corp Transaction History

Prudential PLC

$19.6 Billion
Q3 2024

A detailed history of Prudential PLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Prudential PLC holds 9,983 shares of UTHR stock, worth $3.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

9,983

Previous 9,314 7.18%

Holding current value

$3.6 Million

Previous $2.97 Million 20.6%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$311.04 - $363.55 $208,085 - $243,214	669 Added 7.18%	9,983 $3.58 Million
Q2 2024 Aug 06, 2024	BUY	$228.26 - $319.04 $193,336 - $270,226	847 Added 10.0%	9,314 $2.97 Million
Q1 2024 May 14, 2024	BUY	$210.76 - $249.51 $1.56 Million - $1.85 Million	7,422 Added 710.24%	8,467 $1.95 Million
Q4 2023 Feb 13, 2024	SELL	$214.88 - $256.94 $1.05 Million - $1.25 Million	-4,879 Reduced 82.36%	1,045 $229,000
Q3 2023 Nov 09, 2023	SELL	$211.82 - $248.24 $325,567 - $381,544	-1,537 Reduced 20.6%	5,924 $1.34 Million
Q2 2023 Aug 14, 2023	BUY	$205.19 - $232.99 $89,257 - $101,350	435 Added 6.19%	7,461 $1.65 Million
Q1 2023 May 12, 2023	BUY	$212.99 - $276.17 $330,986 - $429,168	1,554 Added 28.4%	7,026 $1.57 Million
Q4 2022 Feb 08, 2023	SELL	$205.95 - $280.43 $208,421 - $283,795	-1,012 Reduced 15.61%	5,472 $1.52 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $7,115 - $8,545	35 Added 0.54%	6,484 $1.36 Million
Q2 2022 Aug 12, 2022	SELL	$174.81 - $241.14 $3,146 - $4,340	-18 Reduced 0.28%	6,449 $1.52 Million
Q1 2022 May 13, 2022	BUY	$166.16 - $213.96 $1.07 Million - $1.38 Million	6,467 New	6,467 $1.16 Million

Others Institutions Holding UTHR

# of Institutions

671

Shares Held

42.3M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential PLC, based on Form 13F filings with the SEC.

News

Stay updated on Prudential PLC with notifications on news.

Account